MARKET

CALC

CALC

CALCIMEDICA INC
NASDAQ
2.170
-0.030
-1.36%
After Hours: 2.044 -0.126 -5.80% 19:30 09/04 EDT
OPEN
2.130
PREV CLOSE
2.200
HIGH
2.250
LOW
2.090
VOLUME
94.13K
TURNOVER
--
52 WEEK HIGH
36.00
52 WEEK LOW
2.000
MARKET CAP
14.82M
P/E (TTM)
-1.6199
1D
5D
1M
3M
1Y
5Y
1D
CalciMedica Addresses Nasdaq Equity Compliance Amid Bid-Price Risk
TipRanks · 5d ago
Weekly Report: what happened at CALC last week (0824-0828)?
Weekly Report · 08/31 09:49
CalciMedica Announces 1-for-5 Reverse Stock Split
NASDAQ · 08/27 18:13
CalciMedica announces 1-for-5 reverse stock split; shares down
Seeking Alpha · 08/27 13:28
CalciMedica to effect 1-for-5 reverse stock split
TipRanks · 08/27 13:16
*CalciMedica: Split Intended to Bring Co Into Compliance With Minimum Bid Price Requirement for Continued Listing on Nasdaq Cap Market >CALC
Dow Jones · 08/27 13:01
Weekly Report: what happened at CALC last week (0817-0821)?
Weekly Report · 08/24 09:49
CalciMedica Price Target Announced at $9.00/Share by Guggenheim
Dow Jones · 08/20 13:22
More
About CALC
CalciMedica, Inc. is a clinical-stage biopharmaceutical company. The Company focused on developing novel calcium release-activated calcium (CRAC) channel inhibition therapies for inflammatory and immunologic diseases. The Company's technology targets the inhibition of CRAC channels to modulate the immune response and protect against tissue cell injury. Its lead product candidate is Auxora, a potent and selective intravenous formulated small molecule CRAC channel inhibitor containing the active compound zegocractin (formerly referred to as CM4620) that, in animal models, reduced acute epithelial and/or endothelial cell injury and inflammation in organs, such as the pancreas, lungs and kidneys. The Company is conducting a Phase IIb trial (called CARPO) for acute pancreatitis (AP) with systemic inflammatory response syndrome (SIRS), as well as supporting the ongoing Phase I/II asparaginase-induced pancreatic toxicity (AIPT) study (called CRSPA).

Webull offers Calcimedica Inc stock information, including NASDAQ: CALC real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CALC stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading CALC stock methods without spending real money on the virtual paper trading platform.